title: Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment.
abstract: The rate of sustained virologic response (SVR) has increased in patients with chronic hepatitis C (CHC; genotype 1) since triple treatment with pegylated interferon (PEG-IFN), ribavirin (RBV) and telaprevir (TVR) was included in Japanese health insurance. However, side effects such as high-grade anemia and skin disorders means it is important to investigate the extent to which quality of life (QOL) is maintained during treatment. The impact on health-related (HR) QOL, as a result of TVR-based triple treatment was investigated long-term (48 weeks) in 34 patients (18 men, 16 women) following TVR-based triple treatment, using the 36-item short form health survey (SF-36). While scores for physical health were significantly lower during treatment, an improvement was seen in patients who showed complete response to treatment from 12 weeks following treatment (P<0.05). HRQOL improved significantly following completion of TVR-based triple treatment in these complete-responders, with higher scores compared with those prior to treatment. Anemia and skin symptoms appeared frequently during treatment and scores for physical health dropped. Particular care needs to be taken in regards to the management of side effects during TVR treatment. Further evaluations using the SF-36 may help in controlling doses to achieve SVR.
authors.affiliation: Department of Pharmacology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Mitsuyuki
authors.initials: M
authors.lastname: Suzuki
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Ishikawa
authors.affiliation: Department of Pharmacology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Ai
authors.initials: A
authors.lastname: Sakuma
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Abe
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Hiroko
authors.initials: H
authors.lastname: Abe
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Fujiko
authors.initials: F
authors.lastname: Koyama
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Tomomi
authors.initials: T
authors.lastname: Nakano
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Aya
authors.initials: A
authors.lastname: Ueki
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Hirohito
authors.initials: H
authors.lastname: Noguchi
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Erina
authors.initials: E
authors.lastname: Hasegawa
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Shiori
authors.initials: S
authors.lastname: Yamagata
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Miki
authors.initials: M
authors.lastname: Kobayashi
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Ohashi
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Clinical Engineering, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hirosawa
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Department of Nutrition, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Takako
authors.initials: T
authors.lastname: Fukazawa
authors.affiliation: Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan; Administration Bureau of Medical Affairs Section, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Maruyama
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950-1104, Japan.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Yoshida
keywords: chronic hepatitis C; quality of life; short form-36; sustained virologic response; telaprevir